Euho & ISU ABXIS to develop trispecific antibodies based on YH003 sequence
31 Oct 2022 //
BUSINESSWIRE
Eucure Announces Partnership with ISU ABXIS for Tri-specific Antibodies
31 Oct 2022 //
BUSINESSWIRE
Isu Abxis “expects 100% exclusive treatment for Gaucher disease in Algeria”
12 Oct 2022 //
PRESS RELEASE
Isu Abxis, ranked first for two consecutive years in the Algerian Gaucher disease treatment bidding
26 Aug 2022 //
PRESS RELEASE